Chemotherapy treatment for some cancers involves alkylating agents that, while effective against the initial cancer, can in 5% to 10% of patients result in a secondary acute promyelocytic leukemia. We are studying the genetic basis for variations in the carcinogenic response to ankylating agents in mice. Identification of positional candidate genes in mice will allow tests of the relationship of human genetic variations to treatment-related acute promyelocytic leukemia in ongoing research.

Collaborators

Dr. Timothy Graubert, Washington University School of Medicine

Dr. Timothy Ley, Washington University School of Medicine

Grant Funding

Supported by NIH grant NCI P01 CA101937

Publications on the Topic

Funk, R, Maxwell, T, Izumi, M, Edwin, D, Kreisel, F, Ley, T, Cheverud, J & Graubert, T. (2008) 'Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic mice', Blood, vol. 112, no. 4, pp. 1434-1442. doi:10.1182/blood-2008-01-132084 [pdf]

Graubert, T, Cahan, P, Edwin, D, Selzer, R, Richmond, T, Elis, P, Shannon, W, Li, X, McLeod, H, Cheverud, J & Ley, T. (2007) 'A high-resolution map of segmental DNA copy number variation in the mouse genome', PLoS Genetics, vol. 3, no. 1, pp. 0021-0029. doi:10.1371/journal.pgen.0030003 [pdf]

Fenske, T, McMahon, C, Edwin, D, Jarvis, J, Cheverud, J, Minn, M, Mathews, V, Bogue, M, Province, M, McLeod, H & Graubert, T. (2006) 'Identification of candidate alkylator-induced cancer susceptibility genes by genome-wide scanning in mice', Cancer Research, vol. 66, pp. 5029-5038. doi:10.1158/0008-5472.CAN-05-3404 [pdf]